Search

Displaying results 341 - 350 of 7063 in total
  1. Drug

    Theophylline

    go.drugbank.com/drugs/DB00277
    ApprovedInvestigational

    Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. … Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD.

    Mixtures: TUSBRON-A JARABECategories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index
  2. Drug

    Nystatin

    go.drugbank.com/drugs/DB00646
    ApprovedInvestigationalVet approved

    Nystatin is a polyene antifungal drug that has broad-spectrum fungicidal and fungistatic activity against a number of yeasts and fungi, most notably _Candida_ species. … [A188562] Nystatin has a greater antifungal activity than amphotericin B - parenterally administered nystatin, however, is associated with significant toxicity and is not available in a formulation appropriate

    Mixtures: GYNECON - TCategories: Compounds used in a research, industrial, or household setting
  3. Indication

    Liver iron concentration of at least 5 mg Fe per gram of dry weight

    go.drugbank.com/conditions/DBCOND0146507
    Drugs: Deferasirox
    Synonyms: Liver iron concentration of at least 5 mg Fe per gram of dry weight
  4. Drug

    Pantoprazole

    go.drugbank.com/drugs/DB00213
    ApprovedInvestigational

    Pantoprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme at … [A177577, A177580] Pantoprazole doses should be slowly lowered, or tapered, before discontinuing as rapid discontinuation of PPIs such as pantoprazole may cause a rebound effect and a short term increase

    Products: Pantoprazol G.L. 20 mg - magensaftresistente Tabletten, Pantoprazol G.L. 40 mg - magensaftresistente Tabletten
  5. Drug

    Ephedrine

    go.drugbank.com/drugs/DB01364
    ApprovedInvestigational

    [A193698] Ephedrine acts as both a direct and indirect sympathomimetic. … Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine].

    Mixtures: ColdaeWon Cold A, ColdaeWon Cough AProducts: HanPoong Gal Cheon Xin Extract Granules, T-drene 1
  6. Drug

    Amantadine

    go.drugbank.com/drugs/DB00915
    ApprovedInvestigational

    An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. … The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.

    Mixtures: ANTIFLU-DES GEL, BREGAMIN AVCategories: Influenza A M2 Protein Inhibitor
  7. Drug

    Letrozole

    go.drugbank.com/drugs/DB01006
    ApprovedInvestigational

    [A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. … Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.

    Products: Letrozol G.L. 2,5 mg - Filmtabletten, Ag-letrozole
  8. Drug

    Ropinirole

    go.drugbank.com/drugs/DB00268
    ApprovedInvestigational

    Ropinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], [A174547]. … In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous

    Products: ROPINIROL AL 2 MG RET, ROPINIROL AL 3 MG RET
  9. Drug

    Atomoxetine

    go.drugbank.com/drugs/DB00289
    ApprovedInvestigational

    is a limiting factor associated with the use of stimulant medications such as [DB00422], [DB01576], and [DB01255]. … Many contain a blackbox warning stating that CNS stimulants, including methylphenidate-containing products and amphetamines, have a high potential for abuse and dependence.

    Products: Ag-atomoxetine, ATOMOXETIN AL 10MG HKP
  10. Drug

    Rivastigmine

    go.drugbank.com/drugs/DB00989
    ApprovedInvestigational

    Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase. … Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type.

    Categories: Compounds used in a research, industrial, or household settingProducts: Act Rivastigmine Patch 5, Act Rivastigmine Patch 10